Top

Intensive Care Medicine

Published in:

01-07-2003 | Brief Report

Risk factors for piperacillin/tazobactam-resistant Escherichia coli in ICU patients: a clinical study

Authors: Ismaël Mohammedi, Dominique Ploin, Serge Duperret, François Chapuis, Paul Petit

Published in: Intensive Care Medicine | Issue 7/2003

Abstract

Objective

To determine risk factors of infections with piperacillin/tazobactam-resistant Escherichia coli in critical care patients.

Design

Prospective, consecutive sample survey study.

Setting

Surgical intensive care unit (ICU) in a university hospital.

Patients

A consecutive series of 133 patients from whom culture results were positive for E. coli during their ICU stay.

Interventions

None.

Measurements and main results

Multivariate logistic regression analysis identified the following significant independent factors associated with the emergence of a piperacillin/tazobactam-resistant Escherichia coli: prior use of amoxicillin (odds ratio, 4.15) and amoxicillin/clavulanate (odds ratio, 3.25).

Conclusions

Treatment with amoxicillin or amoxicillin/clavulanate is a major risk factor for the detection of piperacillin/tazobactam-resistant E. coli in ICU patients.

Bukharie HA, Abdelhadi MS, Saeed IA, Rubaish AM, Larbi EB (2001) Emergence of methicillin-resistant S. aureus as a community pathogen. Diagn Microbiol Infect Dis 40:1–4CrossRefPubMed

Kaye KS, Harris AD, Gold H, Carmeli Y (2000) Risk factors for recovery of ampicillin-sulbactam-resistant E. coli in hospitalized patients. Antimicrob Agents Chemother 44:1004–1009PubMed

Cheong HJ, Yoo CW, Sohn JW, Kim WJ, Kim MJ, Park SC (2001) Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 33:48–53CrossRefPubMed

Mohammedi I, Tigaud S, Tournadre JP (2000) Emergence of piperacillin/tazobactam-resistant Escherichia coli. Intensive Care Med 26:1584CrossRef

Diekema DJ, Pfaller MA, Jones RN, Doern GV, Winokur PL, Gales AC, Sader HS, Kugler K, Beach M (1999) Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 29:595–607PubMed

Lepelletier D, Caroff N, Reynaud A, Richet H (1999) Escherichia coli: epidemiology and analysis of risk factors for infections caused by resistant strains. Clin Infect Dis 29:548–552PubMed

Sotto A, De Boever CM, Fabbro-Peray P, Gouby A, Sirot D, Jourdan J (2001) Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study. J Clin Microbiol 39:438–444CrossRefPubMed

Johnson CC, Baldessarre J, Levison ME (1997) Peritonitis: update on pathophysiology, clinical manifestations, and management. Clin Infect Dis 24:1035–1045PubMed

Brismar B, Malmborg AS, Tunevall G, Wretlind B, Bergman L, Mentzing LO, Nystrom PO, kihlstrom E, Backstrand B, Skau T (1992) Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 36:2766–2773PubMed

10.

Dupont H, Carbon C, Carlet J (2000) Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. Antimicrob Agents Chemother 44:2028–2033CrossRefPubMed

11.

Rello J, Torres A, Ricart M, Valles J, Gonzalez J, Artigas A, Rodriguez-Roisin R (1994) Ventilator associated pneumonia by Staphylococcus aureus: comparison of methicillin resistant and methicillin sensitive episodes. Am J Respir Crit Care Med 150:1545–1549PubMed

12.

Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C (2002) Pseudomonas aeruginosa ventilator associated pneumonia: comparison of piperacillin resistant and piperacillin susceptible organisms. Clin Infect Dis 34:1047–1054CrossRefPubMed

13.

Garau J, Xercavins M, Rodriguez-Carballeira M, Gomez-Vera JR, Coll I, Vidal D, Llovet T, Ruiz-Bremon A (1999) Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 43:2736–2741PubMed

14.

Leflon-Guibout V, Ternat G, Heym B, Nicolas-Chanoine MH (2002) Exposure to co-amoxiclav as a risk factor for co-amoxiclav-resistant Escherichia coli urinary tract infection. J Antimicrob Chemother 49:367–371CrossRefPubMed

15.

Stapleton P, Wu PJ, King A, Shannon K, French G, Phillips I (1995) Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother 39:2478–2483PubMed

Title: Risk factors for piperacillin/tazobactam-resistant Escherichia coli in ICU patients: a clinical study
Authors: Ismaël Mohammedi
Dominique Ploin
Serge Duperret
François Chapuis
Paul Petit
Publication date: 01-07-2003
Publisher: Springer-Verlag
Published in: Intensive Care Medicine / Issue 7/2003
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-003-1760-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Risk factors for piperacillin/tazobactam-resistant Escherichia coli in ICU patients: a clinical study

Abstract

Objective

Design

Setting

Patients

Interventions

Measurements and main results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Design

Setting

Patients

Interventions

Measurements and main results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2003

Intravenous magnesium sulfate administration in a patient with refractory vasospasm following subarachnoid hemorrhage

Norepinephrine for hypotensive vasodilatation after cardiac surgery: impact on renal function

A novel citrate anticoagulation regimen for continuous venovenous hemodiafiltration

Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey

Cardiac massage in infants

Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis